Combination of Efavirenz and Truvada - COMET Study
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
To characterize the risks (safety and tolerability), effectiveness (continued viral load
suppression and CD4 changes), and benefits (safety, tolerability, adherence, general
satisfaction with the treatment regimen and QoL), of switching from a Combivir (BID) /
efavirenz (QD) regimen to an all QD regimen of Truvada/efavirenz.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Efavirenz Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination